Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (950)	1/6/1998 3:05:00 AM
From: Sigmund	Read Replies (1) \| Respond to of 1894

NeoPath didn't have any substantial data the first time around. They were led to believe that they would get approval from the advisory board but the key guy there was transfered before their meeting. Depo had the same experience with the short cut approach. Now NeoPath has followed the rules and should be successful. If not, I agree with you that they are in big trouble. Their problems clearly would be the greatest but I think you can anticipate a general selloff in the sector because who would want to risk capital if the FDA is out to destroy companies rather than let the marketplace decide who has the best product or combination of products? Assuming they get approval the question then is do they pour money into Pathfinder or make a deal with ACMI or others. That is why an understanding of the architecture of the ACMI product is so important. I